Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 154

Sort by

Sort Order Select

Journal Articles

Survival after First Relapse in Marginal Zone Lymphomas: Prospective Data from the International Observational NF10 Study By the Fondazione Italiana Linfomi

Blood (2024) 144 (Supplement 1): 1639.

https://doi.org/10.1182/blood-2024-207886

Published: 2024

Journal Articles

Mosunetuzumab and Zanubrutinib in Relapsed/Refractory Follicular Lymphoma Patients (MOZART): A Phase II, Chemo-Free Trial from Fondazione Italiana Linfomi (FIL)

Marco Ladetto, Rita Tavarozzi, Matthew Ku, Luca Arcaini, Carola Boccomini, Beatrice Casadei, Annalisa Chiarenza, Annarita Conconi, Ilaria Del Giudice, Michele Merli, Maria Elena Nizzoli, Stefano Luminari

Blood (2024) 144 (Supplement 1): 3042.1.

https://doi.org/10.1182/blood-2024-201305

Published: 2024

Journal Articles

Expanding the Eureka Study: Integrating a Comprehensive Clinical Registry with Molecular Profiling to Advance AL Amyloidosis Research

Blood (2024) 144 (Supplement 1): 1927.1.

https://doi.org/10.1182/blood-2024-200529

Published: 2024

Journal Articles

Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from “FOLL12” Phase III Trial of the Fondazione Italiana Linfomi

Blood (2024) 144 (Supplement 1): 339.

https://doi.org/10.1182/blood-2024-194832

Published: 2024

Journal Articles

Endothelial Dysfunction and Risk of Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation: END-GAME Prospective Study Final Results

Antonio Bianchessi, Irene Defrancesco, Virginia Valeria Ferretti, Cristina Picone, Beatrice Ferrari, Caterina Zerbi, Francesco Romano, Giulia Losi, Erica Consensi, Mara De Amici, Giorgia Testa, Valentina Zoboli, Alessia Taurino, Anna Amelia Colombo, Luca Arcaini, Nicola Polverelli

Blood (2024) 144 (Supplement 1): 3520.

https://doi.org/10.1182/blood-2024-208075

Published: 2024

Journal Articles

Treatment with Venetoclax Positively Modulates Immunological Parameters and T-Cell Features in Patients with Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 1854.

https://doi.org/10.1182/blood-2024-203053

Published: 2024

Journal Articles

Bone Marrow-Free Sequencing of M Protein Genes: A Liquid Biopsy Approach in Monoclonal Gammopathies

Alice Nevone, Arian Sadeghi, Giulia Mazzini, Paolo Milani, Silvia Mangiacavalli, Serena Caminito, Francesca Lattarulo, Monica Russo, Giada Panno, Marco Basset, Claudio Salvatore Cartia, Pietro Benvenuti, Martina Nanci, Claudia Bellofiore, Andrea Foli, Giampaolo Merlini, Luca Arcaini, Giovanni O. Palladini, Mario Nuvolone

Blood (2024) 144 (Supplement 1): 6905.

https://doi.org/10.1182/blood-2024-206861

Published: 2024

Journal Articles

Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study

Blood (2024) 144 (Supplement 1): 4797.

https://doi.org/10.1182/blood-2024-207660

Published: 2024

Journal Articles

Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

Blood (2024) 144 (Supplement 1): 4362.

https://doi.org/10.1182/blood-2024-203004

Published: 2024

Journal Articles

Frontline R-CHOP and BR Have Similar Outcomes By SUV max in Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 3007.

https://doi.org/10.1182/blood-2024-202088

Published: 2024

Journal Articles

An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response

Blood (2024) 144 (Supplement 1): 3328.

https://doi.org/10.1182/blood-2024-200038

Published: 2024

Journal Articles

Persistence of Monotypic Plasma Cells after Chemoimmunotherapy in Patients with Waldenström Macroglobulinemia: A Matter of Time?

Marzia Varettoni, Emilia Cappello, Emanuela Boveri, Virginia Valeria Ferretti, Silvia Zibellini, Gianmarco Favrin, Chiara Varraso, Marco Lucioni, Cristina Picone, Giulia Vittoria Facchetti, Giovanni O. Palladini, Marco Paulli, Luca Arcaini

Blood (2024) 144 (Supplement 1): 4400.

https://doi.org/10.1182/blood-2024-207850

Published: 2024

Journal Articles

EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study

Blood (2024) 144 (Supplement 1): 4395.

https://doi.org/10.1182/blood-2024-201269

Published: 2024

Journal Articles

HLA-DQ8 Haplotype Increases the Risk of Relapse after Allogeneic Stem Cell Transplantation Possibly Affecting Graft-Versus-Leukemia: A Single-Center Study on 400 Patients

Giulia Losi, Annamaria Pasi, Carmen Tania Prezioso, Bianchessi Antonio, Caterina Zerbi, Irene Defrancesco, Anna Amelia Colombo, Francesco Romano, Valentina Da Prat, Alessia Taurino, Valentina Zoboli, Luca Arcaini, Cesare Perotti, Riccardo Caccialanza, Nicola Polverelli

Blood (2024) 144 (Supplement 1): 2168.

https://doi.org/10.1182/blood-2024-207802

Published: 2024

Journal Articles

EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab

Blood (2024) 144 (Supplement 1): 1616.

https://doi.org/10.1182/blood-2024-204593

Published: 2024

Journal Articles

Longitudinal Monitoring of Circulating Tumor DNA to Predict Survival in Newly Diagnosed Peripheral T-Cell Lymphoma Patients

Blood (2024) 144 (Supplement 1): 1580.

https://doi.org/10.1182/blood-2024-201391

Published: 2024

Journal Articles

Hepatitis C Virus and Hepatitis B Virus in Indolent Lymphomas: Prospective Data from the International Observational NF10 Study

Blood (2024) 144 (Supplement 1): 3020.

https://doi.org/10.1182/blood-2024-207163

Published: 2024

Journal Articles

A SWOT-Consensus for CAR-T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection

Monia Marchetti, Paolo Corradini, Luca Arcaini, Stefania Bramanti, Alice Di Rocco, Marco Ladetto, Stefano Luminari, Luigi Rigacci, Pier Luigi Zinzani

Blood (2024) 144 (Supplement 1): 2269.

https://doi.org/10.1182/blood-2024-198647

Published: 2024

Journal Articles

High Ferritin and C-Reactive Protein Levels Result in Poor Clinical Outcome in R/R Large B-Cell Lymphoma Patients Despite Significant Anti-CD19 CAR-T Cell In Vivo Expansion

Blood (2024) 144 (Supplement 1): 4786.

https://doi.org/10.1182/blood-2024-201399

Published: 2024

Journal Articles

Progression-Free Survival but Not Overall Survival Is Superior in Relapsed/Refractory Large B-Cell Lymphomas Treated with Axicabtagene Ciloleucel Compared to Tisagenlecleucel: Results of the CART-SIE Real Life Italian Study

Blood (2023) 142 (Supplement 1): 2118.

https://doi.org/10.1182/blood-2023-189300

Published: 2023

NARROW

Survival after First Relapse in Marginal Zone Lymphomas: Prospective Data from the International Observational NF10 Study By the Fondazione Italiana Linfomi

Mosunetuzumab and Zanubrutinib in Relapsed/Refractory Follicular Lymphoma Patients (MOZART): A Phase II, Chemo-Free Trial from Fondazione Italiana Linfomi (FIL)

Expanding the Eureka Study: Integrating a Comprehensive Clinical Registry with Molecular Profiling to Advance AL Amyloidosis Research

Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from “FOLL12” Phase III Trial of the Fondazione Italiana Linfomi

Endothelial Dysfunction and Risk of Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation: END-GAME Prospective Study Final Results

Treatment with Venetoclax Positively Modulates Immunological Parameters and T-Cell Features in Patients with Chronic Lymphocytic Leukemia

Bone Marrow-Free Sequencing of M Protein Genes: A Liquid Biopsy Approach in Monoclonal Gammopathies

Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study

Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

Frontline R-CHOP and BR Have Similar Outcomes By SUV max in Follicular Lymphoma

An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response

Persistence of Monotypic Plasma Cells after Chemoimmunotherapy in Patients with Waldenström Macroglobulinemia: A Matter of Time?

EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study

HLA-DQ8 Haplotype Increases the Risk of Relapse after Allogeneic Stem Cell Transplantation Possibly Affecting Graft-Versus-Leukemia: A Single-Center Study on 400 Patients

EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab

Longitudinal Monitoring of Circulating Tumor DNA to Predict Survival in Newly Diagnosed Peripheral T-Cell Lymphoma Patients

Hepatitis C Virus and Hepatitis B Virus in Indolent Lymphomas: Prospective Data from the International Observational NF10 Study

A SWOT-Consensus for CAR-T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection

High Ferritin and C-Reactive Protein Levels Result in Poor Clinical Outcome in R/R Large B-Cell Lymphoma Patients Despite Significant Anti-CD19 CAR-T Cell In Vivo Expansion

Progression-Free Survival but Not Overall Survival Is Superior in Relapsed/Refractory Large B-Cell Lymphomas Treated with Axicabtagene Ciloleucel Compared to Tisagenlecleucel: Results of the CART-SIE Real Life Italian Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only